Tender detail
Non-exclusive medicine rebate agreement for pamidronic acid
Summary
DAK-Gesundheit intends to conclude non-exclusive medicine rebate agreements with interested pharmaceutical companies for medicines containing pamidronic acid (ATC M05BA03), as specified in the contract annex. The agreements are scheduled to run from 1 January 2027 to 31 December 2028, with one optional 12-month extension, and will end automatically when an exclusive agreement for the active ingredient takes effect.
More tender information after sign-in
The public view shows key tender details. Sign in to open official links, documents and AI tender support.